N
AVNR

Natixis’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Natixis’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-17,700
Closed -$65K – 574
2014
Q1 		$65K Buy
+17,700
New +$67.5K ﹤0.01% 476

Other funds holding AVNR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Natixis's AVNR Position: Q2 2014 in Review

Natixis sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q2 2014, closing a stake of 17,700 shares — an estimated $65K sold.

Natixis first reported a position in AVNR in Q1 2014 and held it in 1 quarter. The position peaked at $65K in Q1 2014. 115 funds tracked by Wall St. Rank hold AVNR as of Q2 2014.

  • Natixis reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q2 2014 after selling out during the quarter.
  • Natixis sold 17,700 AVANIR PHARMACEUTICALS, INC CL A shares in Q2 2014, an estimated $65K.
  • Natixis first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q1 2014 and held it in 1 quarter.
  • Natixis's AVANIR PHARMACEUTICALS, INC CL A position peaked at $65K in Q1 2014.
  • 115 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q2 2014.

Based on Natixis's 13F filing for Q2 2014, filed 14 Aug 2014.